Abstract
Drug resistance contributes to the poor prognosis of acute nonlymphocytic leukemia (ANLL) [1, 2]. In order to overcome drug resistance, knowledge of its exact nature is required.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wiernik PH (1989) Acute leukemias. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 1809–1835
Hiddemann W, Büchner T (1990) Treatment strategies in acute myeloid leukemia ( AML ). Blut 60: 163–171
Pastan I, Gottesman MM (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl cancer Inst 81: 116–124
Pirker R, Goldstein LJ, Ludwig H, Linkesch W, Lechner C, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun 1: 141–144
Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDRI gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712
Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R (1991) MDRI gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer In press
Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I (1990) MDRI transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haemato1 75: 340–345
Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet is 135–137
Sonneveld P, Nooter K (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 75: 208–211
Pirker R, Keilhauer G, Raschack M, Lechner C, Ludwig H (1990) Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 45: 916–919
Pirker R, FitzGerald DJP, Raschack M, Zimmermann F, Willingham MC, Pastan I (1989) Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res 49: 4791–4795
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pirker, R., Wallner, J., Geissler, K., Bettelheim, P., Linkesch, W., Lechner, K. (1992). Expression of the MDR1 Gene and Treatment Outcome in Acute Nonlymphocytic Leukemia. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive